LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

LLY

1,008.05

-0.05%↓

JNJ

229.41

-0.66%↓

ABBV

211.8

+0.02%↑

UNH

396.1

-0.48%↓

AZN

181.62

-2.05%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

12.45 1.63

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.01

Max

12.59

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.857 51.415
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+57.85% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.2B
Ankstesnė atidarymo kaina	10.82
Ankstesnė uždarymo kaina	12.45

Naujienos nuotaikos

By Acuity

50%

171 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-14 22:44; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

2026-05-14 22:27; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

2026-05-14 22:12; UTC

Uždarbis

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

2026-05-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs

2026-05-15 00:00; UTC

Uždarbis

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

2026-05-14 23:57; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Stake Sales Aim to Secure Funds for Future Investments

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

2026-05-14 23:56; UTC

Rinkos pokalbiai

Gold Prices Rise on Strong Demand -- Market Talk

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

2026-05-14 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

2026-05-14 23:47; UTC

Uždarbis

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

2026-05-14 23:47; UTC

Uždarbis

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

2026-05-14 23:28; UTC

Rinkos pokalbiai

New Zealand's Economy Faltering Amid Shocks -- Market Talk

2026-05-14 23:00; UTC

Rinkos pokalbiai

Australia's One Nation Party Leads In The Polls -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Court Decision 'Negative But Balanced' for Coles -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-14 22:35; UTC

Rinkos pokalbiai

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

2026-05-14 22:11; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Agrees to Sell Marc Jacobs -- WSJ

2026-05-14 22:06; UTC

Rinkos pokalbiai

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

2026-05-14 22:00; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q EPS 18c >NU

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q Rev $4.97B >NU

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

57.85% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 57.85%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

171 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.